Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial ...

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) to target the active or ON-state of multiple forms of RAS mutations.

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) to target the active or ON-state of multiple forms of RAS mutations.

The genetic makeup of his tumor showed a specific gene mutation. "The gene can have a ... "These are the so-called RAS inhibitors." Research indicates that RAS inhibitors target a specific protein ...

Title: QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity Date and Time: Wednesday, April 30, 2025; 9:00 AM - 12:00 PM ...

VVD-159642, Vividion's fourth clinical-stage program stemming from its chemoproteomics discovery platform, is designed to improve patient outcomes by inhibiting RAS-PI3Ka, a key signaling pathway ...